← Eichor
Study identifier: NCT07643948 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impacts of HIV Treatment Regimens on Archived Drug Resistance

Condition: HIV -1 Infection · Antiretroviral Therapy · Drug Resistance, Microbial  ·  Sponsor: Chinese University of Hong Kong

PhaseN/A
Planned participants420
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The study aims to determine the prevalence of drug resistance mutation (DRM) in virally suppressed HIV infection, and the impacts of regimen change and the presence of low level viremia. Adults living with HIV infection on antiretroviral therapy (ART) with full viral suppression would be recruited. Cases are patients planning for regimen switch, while controls are those with and without low level viraemia (LLV) not planned for switch. Blood samples would be collected before and after switch. Sequencing would be performed to identify DRM present in HIV-1 proviral DNA.

This description comes directly from the study's public registry record.

Talk to the study team

Shui Shan Lee, MD  ·  +852 22528812  ·  sslee@cuhk.edu.hk

Ngai Sze Wong, PhD  ·  +852 22528862  ·  candy_wong@cuhk.edu.hk

Always discuss trial participation with your own doctor first.

Locations (1)

S.H. Ho Research Centre for Infectious Diseases, The Chinese University of Hong KongHong Kong, Hong Kong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07643948